All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Protocol-specified interim analysis conducted by the Independent Data Monitoring Committee demonstrated that patients treated with Libtayo monotherapy had a significant increase in overall survival.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Monalizumab,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 23, 2020
Details:
Monalizumab, Innate’s lead partnered asset. On April 24, 2015, Innate signed a co development and commercialization agreement with AstraZeneca to accelerate and broaden the development of monalizumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedopi
Therapeutic Area: Oncology Product Name: OSE-2101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The primary endpoint, 1-year overall survival rate in the mITT** population, was achieved in patients treated with Tedopi®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Presentations will feature promising data across multiple cancers, including renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, prostate cancer and various neuroendocrine tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedopi
Therapeutic Area: Oncology Product Name: OSE-2101
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Step-1 results of OSE Immunotherapeutics' Phase 3 clinical trial of investigational product Tedopi®, called Atalante 1, in HLA-A2 positive non-small cell lung cancer patients after failure from immune checkpoint inhibitors will be presented at the ESMO Virtual Congress 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 02, 2020
Details:
Ipsen will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Irinotecan,Oxaliplatin,Leucovorin Calcium
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) (NALIRIFOX) to gemcitabine + nab-paclitaxel in the first-line setting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Irinotecan,Oxaliplatin,Leucovorin Calcium
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
US FDA has granted the company Fast Track designation for the investigational use of ONIVYDE in combination with 5- fluorouracil/leucovorin & oxaliplatin, for patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
